~~<i id='C4B78D2CCD'><strike id='C4B78D2CCD'><tt id='C4B78D2CCD'><pre id='C4B78D2CCD'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

Wikipedia

author：fashion 2025-09-28 00:51:55 - browse：599

Bruce Broussard. -- health business coverage from STAT — Humana CEO Bruce Broussard Jason DeCrow/AP

Bruce Broussard, CEO of health insurance giant Humana, will step down next year after leading the company for more than a decade.

Humana named Jim Rechtin — who is the CEO of Envision Healthcare, the controversial physician staffing firm that is working its way through bankruptcy — as Broussard’s replacement. Rechtin will serve as president and chief operating officer starting Jan. 8 and then take over as CEO in the “latter half of 2024,” the company said in a news release.

Humana’s stock fell by more than 2% on the news Wednesday morning.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Biden outlines 'new path' to provide student loan relief after Supreme Court rejection
Next article： World's first CRISPR

entertainment

leisure time

hotspot

explore

hotspot

NovoNordiskviaAPPHILADELPHIA—NovoNordisk’sobesitydrugWegovynotablycuttheriskofheartattacksinalandmar

WSS

Congress must reauthorize a committee to support older Americans

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

Hospitals look to new technology to keep health care workers safe

Too many hospitalized Covid

Artificial intelligence use in health care faces greater scrutiny in 2024

Ebola vaccine can save some who are already sick, per new study

hotspot

Wikipedia

entertainment

Heart attack and stroke risk calculators need revising

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Too many hospitalized Covid

ChatGPT in medicine: STAT answers readers' burning questions

Abbott's new heart device gets FDA advisory panel nod

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Astellas still sees hope in its gene therapy after four deaths

Heart attack and stroke risk calculators need revising

Congress might make insulin pumps more accessible to the blind

leisure time

Ebola vaccine can save some who are already sick, per new study

Poor hospice wound care hurts patients and families

In key trial, Verve's treatment lowers cholesterol levels in patients

NYU radiologists take on the challenge of expensive MRI machines

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

Anthos stroke drug appears safer than common blood thinner

hotspot

hotspot

explore

hotspot